Antibody‐Directed Cancer Therapy Using Cubic‐Shaped Magnetic Nanoparticles for Combined Hyperthermia and Drug Release
ChemMedChem · 2026
DOI: 10.1002/cmdc.202500632 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2026. Verfasst von S S Pawar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physics, The New College, Shivaji University, Kolhapur, Maharashtra, 416012, India. Hauptthemen laut MEDLINE: Doxorubicin, Magnetite Nanoparticles, Antineoplastic Agents, Hyperthermia, Induced. Die Arbeit nennt 77 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Magnetic nanoparticles (MNPs) have emerged as a promising tool for cancer therapy, providing significant potential for multimodal cancer treatments that include chemotherapy, magnetic hyperthermia, and bioactive targeting. The physicochemical properties of MNPs, including size, surface chemistry, and magnetic properties, play a crucial role in determining their therapeutic effectiveness and overall performance in multimodal cancer therapy. The present study introduces a magnetic nanoformulation ( c MNP‐mPEG‐Dox‐Ab) nanobioengineered for an integrated therapeutic approach. The cubic‐shaped MNPs ( c MNP) are functionalized with a biocompatible polymer, mPEG‐NH 2 , to immobilize anti‐HER2 antibody and the anticancer drug doxorubicin. The nanoformulation exhibits a controlled drug release in response to pH and temperature stimuli. Notably, under an alternating magnetic field (AMF), 64% drug release is observed at an acidic pH, which mimics the tumor microenvironment. Cytotoxicity studies on the HCC1954 breast cancer cells reveal that the nanoformulation without an anti‐HER2 antibody induces 25% cell death, which increases to 52% upon conjugation with the anti‐HER2 antibody, confirming the bioactive targeting effect. Apoptosis studies demonstrate a significant increase in the apoptotic cell population under hyperthermic conditions relative to the physiological temperature. This study underscores the potential of c MNP‐mPEG‐Dox‐Ab nanoformulation to enhance the precision and therapeutic efficacy of multimodal cancer therapy through bioactive targeting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physics, The New College, Shivaji University, Kolhapur, Maharashtra, 416012, India.
- Semiconductor Physics, Chemnitz University of Technology, 09107, Chemnitz, Germany.
- Functional Magnetic Materials, Chemnitz University of Technology, 09107, Chemnitz, Germany.
- Department of Medical Physics, Centre of Interdisciplinary Research, D. Y. Patil Education Society, Kolhapur, 416003, Maharashtra, India.
- Center for Materials, Architectures, and Integration of Nanomembranes (MAIN), Chemnitz University of Technology, 09107, Chemnitz, Germany.
- Regrow Biosciences Pvt Ltd, Lonavala, Maharashtra, 41040, India.
ORCID-Profile: S S Pawar, O Selyshchev, L Rasabathina, V M Khot, O Hellwig, V V Kedage, D R T Zahn, G Salvan, A D Chougale, P B Patil
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Pawar, S. S., Selyshchev, O., Rasabathina, L., Khot, V. M., Hellwig, O., Kedage, V. V., Zahn, D. R. T., Salvan, G., Chougale, A. D., & Patil, P. B. (2026). Antibody‐Directed Cancer Therapy Using Cubic‐Shaped Magnetic Nanoparticles for Combined Hyperthermia and Drug Release. ChemMedChem. https://doi.org/10.1002/cmdc.202500632
Vancouver
Pawar SS, Selyshchev O, Rasabathina L, Khot VM, Hellwig O, Kedage VV, et al. Antibody‐Directed Cancer Therapy Using Cubic‐Shaped Magnetic Nanoparticles for Combined Hyperthermia and Drug Release. ChemMedChem. 2026. doi:10.1002/cmdc.202500632
BibTeX
@article{Pawar2026,
author = {Pawar, S S and Selyshchev, O and Rasabathina, L and Khot, V M and Hellwig, O and Kedage, V V and Zahn, D R T and Salvan, G and Chougale, A D and Patil, P B},
title = {Antibody‐Directed Cancer Therapy Using Cubic‐Shaped Magnetic Nanoparticles for Combined Hyperthermia and Drug Release},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.202500632}
}
EUVIMED